The U.S. Supreme Court declined on Monday to review former pharmaceutical executive Martin Shkreli’s challenge to a $64 million disgorgement order, which was imposed after his alleged scheme to raise the price of a life-saving drug by 4,000%. The court’s refusal to hear Shkreli’s petition marks the latest development in the long-running legal saga stemming from his involvement with Daraprim, a drug used to treat parasitic infections.
Shkreli’s Appeal Rejected Without Explanation
Shkreli had sought to challenge the substantial disgorgement order, arguing that he shouldn’t be held responsible for the profits his company allegedly gained through monopolizing the Daraprim market. However, the Supreme Court denied his petition without explanation, as is common practice, leaving the Second Circuit’s ruling in place. This decision keeps Shkreli on the hook for up to $64 million in profits.
The petition arose from an antitrust lawsuit brought by the Federal Trade Commission (FTC) and several states, accusing Shkreli of orchestrating a scheme to block competitors and inflate Daraprim’s price from $17.50 to $750 per tablet. In addition to the disgorgement order, Shkreli has been banned from the pharmaceutical industry for life, though he did not contest that aspect of the ruling in his Supreme Court appeal.
Antitrust Violations and Disgorgement Order
The case, which became a defining moment in the public’s perception of pharmaceutical pricing practices, centers on Shkreli’s actions as the head of Vyera Pharmaceuticals, formerly known as Turing Pharmaceuticals. Enforcers accused Shkreli of acquiring Daraprim in 2015 and then enacting a series of anticompetitive measures to block generic drug manufacturers from entering the market. These actions allegedly included restricting access to drug samples for regulatory testing and signing exclusive supply contracts for the active ingredient in Daraprim.
